Dr. Reddy's Laboratories (RDY) Stock: Buy, Sell, or Hold?
RDY - Dr. Reddy's Laboratories Limited American Depositary Shares
$12.25
0.00 (0.00%)
â˛
5d:
+0.0%
30d:
+0.66%
90d:
-14.69%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 23, 2026
18d
Get Alerted When RDY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RDY is fairly priced but lacks strong directional signals. At -2.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RDY is fairly priced but lacks strong directional signals. At -2.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.99
Based on -2.0% avg growth
INTRINSIC VALUE TODAY
$8.68
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RDY is currently trading at $12.25, which is considered fair relative to its 30-day fair value range of $11.89 to $12.45. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.3). Remarkably, the market is currently pricing in an annual earnings decline of 2.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, RDY is in a downtrend. The price is currently testing key support at $12.07. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RDY is in a downtrend. The price is currently testing key support at $12.07. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.89 -
$12.45
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($13.29)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.89 -
$12.45
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$12.08
Resistance Level
$12.99
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.24
Wall Street Target
$13.29
(+8.5%)
Revenue Growth (YoY)
-5.6%
Earnings Growth (YoY)
-68.7%
Profit Margin
10.0%
Valuation Discount vs History
-2.0% cheaper
PE vs Historical
0.2 vs 0.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.0%
(market-implied from PE analysis)
1-Year Target
$12.00
(-2%)
2-Year Target
$11.76
(-4%)
3-Year Target
$11.53
(-6%)
3-Yr Target (if PE normalizes)
(PE: 0â0)
$14.63
(+19%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: -8.0%)
$823.00
(+6618%)
Base:
(SPY PE: 0.2, Growth: -8.0%)
$9.54
(-22%)
Bear:
(PE: 0.2, Growth: -8.0%)
$8.11
(-34%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (0x PE) as earnings recover.
Trailing PE: 30.62 | Current EPS (TTM): $0.40
Bull Case
$26.95
(+120%)
Analyst growth 100.0%, PE expands to 33.7
Base Case
$24.50
(+100%)
Market implied 100.0%, PE stable at 30.6
Bear Case
$8.33
(-32%)
Severe decline -20.0%, PE contracts to 26.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.2 to 0.3
Stabilization Target:
$15.55
(+26.9%)
PE Expansion Potential:
+26.9%
Share & Embed Analysis
Last updated: October 04, 2026 2:30 PM ET
Data refreshes hourly during market hours. Next update: 3:30 PM
Data refreshes hourly during market hours. Next update: 3:30 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
28 analysts |
$208 | 62 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 62 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 59 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$42 | 54 HOLD |
